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Short Communication
Brain Cell Reservoirs of Latent Virus in
Presymptomatic HIV-Infected Individuals
Katherine A. Thompson,* Catherine L. Cherry,†
Jeanne E. Bell,‡ and Catriona A. McLean*
From the Pathology Research Laboratory,* Anatomical Pathology
Unit and the Centre for Virology,† Burnet Institute, Infectious
Diseases Unit, The Alfred Hospital, Department of Medicine,
Monash University, Melbourne, Australia; and the
Neuropathology Unit,‡ University of Edinburgh, Western General
Hospital, Edinburgh, United Kingdom
We detected HIV-1 DNA in pure populations of
perivascular macrophages, parenchymal microglia,
and astrocytes, isolated using laser microdissection
from brain tissue of five untreated individuals who
died in the presymptomatic stage of infection from
non-HIV causes. HIV-1 DNA was detected in the
three cell populations, most consistently in perivas-
cular macrophages, without evidence of productive
infection. The percentage of PCR reactions detect-
ing HIV-1 DNA in perivascular macrophages corre-
lated inversely with peripheral blood CD4 counts.
These findings demonstrate that brain cell reser-
voirs of latent HIV-1 exist before pathological HIV
encephalitis and suggest that perivascular macro-
phage trafficking of latent virus into the brain in-
creases with immunosuppression. (Am J Pathol 2011,
179:1623–1629; DOI: 10.1016/j.ajpath.2011.06.039)
Establishing whether a specific cellular site of latent
HIV-1 infection exists within the brain before the devel-
opment of pathological HIV encephalitis (HIVE) is crit-
ical to understanding the nature of the central nervous
system (CNS) HIV reservoir. The brain cell types or
type within which virus is latent (DNA detection in the
absence of detectable viral protein) has not been es-
tablished. Studies have been hampered by the limited
availability of autopsy brain tissue from individuals who
have died before end-stage HIV disease and by tech-
niques that lack both cell specificity and sensitivity for
low copy viral DNA detection.
We studied a unique cohort of HIV-positive, presymptom-
atic individuals who died before pathological evidence of
HIVE and used microdissection techniques to obtain pure
cell populations from specific brain regions. Genomic DNA
extracted from astrocytes, perivascular macrophages, and
parenchymal microglia were used as a template in a highly
sensitive, triple-nested PCR to amplify and sequence a
119-bp fragment of the HIV-1 gag gene. These techniques
achieved a specificity and sensitivity not previously possible
and enabled us to detect latent HIV-1 in resident brain cells,
suggesting that cellular viral reservoirs exist in the brain
before onset of HIVE.
Materials and Methods
Brain Pathology
Autopsy brain tissue blocks were obtained from the Med-
ical Research Council HIV Tissue Resource (Edinburgh)
and were examined according to guidelines endorsed by
the Alfred Hospital Human Ethics committee (HREC #81/
07). Five individuals with untreated, established HIV-1
infection who died from HIV-unrelated causes were ex-
amined. They had no evidence of HIVE, nor of any other
HIV-related neuropathology at autopsy. Similarly, there
was no evidence of any AIDS-defining infection, malig-
nancy, or neurological disease.1 These individuals were
therefore considered to be presymptomatic, with a spec-
trum of immunodeficiency. Brain tissue from two HIVE
and two HIV-negative individuals were used as positive
and negative controls, respectively. HIVE was diag-
nosed pathologically by productive infection of HIV-1
(as evidenced by p24 expression) of perivascular mac-
rophages with or without giant cells with evident micro-
glia activation and/or microglial nodules. Brains were
routinely fixed, sectioned, and embedded. Using clean
microtome blades, sections (5 m thick) from the oc-
cipital cortex were cut, placed onto charged glass
slides, and air-dried overnight before immunohisto-
chemical staining.
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Cell and HIV-1 Identification
Routine H&E staining was performed. A 1:50 dilution of a
glial fibrillary acidic protein (GFAP) antibody (Zymed
Laboratories, South San Francisco, CA) was used to de-
tect astrocytes. A 1:200 dilution of a CD68 antibody
(DakoCytomation, Glostrup, Denmark) was used to de-
tect cells of macrophage lineage. Perivascular macro-
phages and parenchymal microglia were distinguishable
by shape and location. A 1:40 dilution of p24 antibody
(DakoCytomation) was used to detect HIV-1 protein. All
antibodies were used with the avidin-biotin complex
method and a diaminobenzidine hydrogen peroxide
product as the colorimetric substrate. In situ proximity
ligation assay (Duolink II; Olink Bioscience, Uppsala,
Sweden) was also performed for single HIV-1 protein
recognition using a 1:40 dilution of p24 antibody
(DakoCytomation), according to the manufacturer’s proto-
col. Tissue sections were assessed by a neuropathologist
(C.A.M.) and with Image-Pro Plus 6.0 image analysis soft-
ware (MediaCybernetics, Bethesda, MD) for immunoposi-
tive cells, as described previously.2
Laser Microdissection
Perivascular macrophages, parenchymal microglia, and
astrocytes within the white matter from the occipital re-
gion of the cerebral cortex were identified as described
above and were laser dissected (P.A.L.M. Microlaser
Technologies, Oberkochen/Bernried, Germany) from un-
covered IHC stained sections on slides and collected as
pure cell populations for subsequent analysis. The occip-
ital region provided a representative view of the immune
reaction to HIV-1 in the brain.2 At least 200 cells spanning
the entire tissue section were collected from each of the
three cell populations, in duplicate from each individ-
ual.3,4 Neurons were microdissected from adjacent cor-
tical regions to provide internal negative controls, as de-
scribed previously.3 Genomic DNA was extracted using
the Arcturus PicoPure DNA extraction kit (Applied Bio-
systems, Foster City, CA) according to the manufactur-
er’s protocol.
Amplification and DNA Sequence Analysis of
HIV-1 GAG
HIV-1 gag sequences were amplified from genomic DNA
prepared from laser dissected, captured cell populations.
KAPA2G robust hot start DNA polymerase (Kapa Biosys-
tems, Boston, MA) was used to generate a 119-nucleotide
(nt) gag fragment in a highly sensitive triple-nested PCR
strategy using 40 cycles per round, as described previ-
ously.3,5 Primers used were designed against a highly con-
served gag region from the HIV-1 clade B consensus se-
quence. The nucleotide (nt) numbers represent their
position relative to the HIV-1 NL4.3 strain: round 1: forward
5=-AGAACCAAGGGGAAGTGACA-3= nt 1476-1496; reverse
5=-TTGGACCAACAAGGTTTCTGT-3= nt 1761-1741. Round
2: forward 5=-CCCTTCAGGAACAAATAGGATG-3= nt
1514–1536; reverse 5=-GAAGCTTGCTCGGCTCTTAG-3= nt
1718-1699. Round 3: forward 5=-TCCACCTATCCCAGTAG-
Table 1. Clinical Backgrounds, Immunohistochemical Detection, and PCR Detection of HIV-1 gag DNA in Brain Cell Populations of
Study Subjects








75 M 29 Sepsis   0 HIVD
138 M 59 Sepsis   6 HIVD
Mean
HIV-positive, presymptomatic
245 M 35 Cirrhosis   18 No CI
205 M 34 OD   80 No CI
305 M 34 Cirrhosis   229 No CI
281 F 29 OD   260 ND
240 M 40 OD   496 No CI
Mean
HIV-negative
310 M 45 RTA   ND No CI
170 M 60 Sepsis**   ND No CI
Mean
(table continues)
*Last recorded CD4 T-cell count.
†Detection of HIV-1 gag DNA from microdissected cell populations by triple-nested PCR. The number of positive (HIV-1 gag DNA detected) PCR
reactions divided by the total number of triple-nested PCRs performed on each cell population (also expressed as a percentage).
‡Mean of 10 fields counted under a 40 objective.
§Total area stained (expressed as a percentage).
¶Increased activation or cell numbers compared with corresponding brain cell populations in the HIV-positive presymptomatic group and HIV-negative
group (P  0.05).
Increased activation or cell numbers compared with corresponding brain cell populations in the HIV-negative group (P  0.05).
**Immunosuppressed (lung transplant recipient).
Astro, astrocytes; CI, cognitive impairment; F, Female; HIVD, HIV-associated dementia; M, Male; Micro, parenchymal microglia; ND, no data; OD,
alcohol or drug overdose; PVM, perivascular macrophage; RTA, road traffic accident.
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GAGAA-3= nt 1548-1569; reverse 5=-AGGGTTCCTTTGGTC-
CTTGT-3= nt 1666-1647.
The sensitivity of the triple-nested PCR was deter-
mined using a plasmid-containing HIV DNA of known
concentration as a template in the triple-nested PCR.5
Cell populations were collected in duplicate, and the triple-
nested PCR was performed on each cell population at least
10 times to determine the frequency of detection. Integrity of
DNA was established by performing a similar highly sensi-
tive PCR analysis of cellular GAPDH levels, as described
previously.3 PCR products were sequenced at the Applied
Genetic Diagnostics laboratory, Melbourne University
(Parkville, Australia), and were aligned against the clade B
consensus sequence using DNAMAN 6.0 software (Lyn-
non, Pointe-Claire, QC, Canada).
Statistical Analysis
Quantitative data were analyzed using nonparametric
tests (Mann–Whitney U-test, Spearman rank correla-
tion) in the Stata 10.1 software package (StataCorp,
College Station, TX).
Results
Clinical details are summarized in Table 1. Neuropatho-
logical analysis detected microglial and astrocytic reac-
tivity in the absence of HIV-1 p24 protein in brain tissue
from the five cases (Figure 1). Image analysis confirmed
increased microglia and astrocyte activation within
cases, compared with HIV-1 negative controls (P 0.05).
Activation of all cell types within HIVE was increased,
compared with the cases and HIV-1-negative groups
(P  0.05) (Table 1).
Triple-nested PCR was used to determine the presence
of HIV-1 gag DNA within genomic DNA extracted from
perivascular macrophages, parenchymal microglia, and
astrocytes. The sensitivity of the triple-nested PCR was de-
termined to be 1 copies of HIV-1 gag DNA per reaction.
The gag region was successfully amplified from perivascu-
lar macrophages for all five cases (Table 1 and Figure 2A).
The gag region was successfully amplified from astrocytes
in four of the five cases (not from subject code no. 240), and
from parenchymal microglial cells in four of the five cases
(not from subject code no. 305). The gag region was suc-
cessfully amplified in all cell populations in both HIVE indi-
viduals and was detected in a greater proportion of perivas-
cular macrophages compared with presymptomatic
individuals. HIV-1 gag DNA was not detected in cell popu-
lations fromHIV-1-negative controls or cortical neurons from
HIV-1-infected individuals. Sequence analysis confirmed
HIV-1 gag DNA fragments were amplified from the cases
specified. Mean percentage interpatient sequence variation
in the gag gene is 5%, and the degree of sequence variation
in gag correlates with the length of HIV-1 infection.6 Our
sequence analysis in a short segment of the HIV-1 gag gene
showed a mean variation from the clade B consensus se-
quence of 6% in the two HIV encephalitic individuals and
3% in the HIV presymptomatic cases, reflecting expected
variation between patients. Resulting amino acid se-
quences were aligned against the HIV-1 gag consensus
sequence (Figure 2C).
Table 1. Continued
Detection of HIV-1 gag DNA
[n/N (% detection rate)†] Cell count‡ (no.) IHC staining§ (%)
PVM Micro Astro PVM Micro Astro PVM, Micro Astro
3/11 (27) 1/11 (9) 2/18 (11) 7.40 29.80 9.80 0.143167 0.814018
4/12 (33) 1/12 (8) 4/24 (17) 7.00 24.80 9.20 0.118800 0.742597
30 9 14 7.20¶ 27.30¶ 9.50* 0.130984¶ 0.778308¶
4/15 (27) 1/10 (10) 1/11 (9) 2.70 9.90 7.20 0.012492 0.593083
2/10 (20) 2/18 (11) 1/10 (10) 1.50 18.10 4.60 0.012518 0.262532
2/10 (20) 0/18 (0) 4/29 (14) 0.40 8.90 4.20 0.012617 0.116776
2/20 (10) 2/20 (10) 5/22 (23) 2.90 9.80 1.80 0.026765 0.257186
1/12 (8) 6/16 (38) 0/13 (0) 3.10 10.40 3.20 0.082078 0.410261
17 14 11 2.12 11.42 4.2 0.029294 0.327968
0/10 (0) 0/10 (0) 0/11 (0) 0.70 4.70 3.10 0.002492 0.056377
0/10 (0) 0/10 (0) 0/11 (0) 0.40 3.20 2.20 0.004189 0.034862
0 0 0 0.55 3.95 2.65 0.003341 0.045620
HIV Reservoirs in Brain Cells 1625
AJP October 2011, Vol. 179, No. 4
The frequency with which HIV-1 gag DNA was de-
tected by triple-nested PCR in the perivascular macro-
phages of HIV-1-positive individuals correlated inversely
with the peripheral blood CD4 count (Spearman correla-
tion,   0.93, P  0.003) (Figure 2B).
Discussion
The optimal time to begin combination antiretroviral ther-
apy for chronically infected individuals remains to be
determined, although current guidelines recommend
starting treatment when CD4 cell counts are less than 350
cells/mL.7–9 Preventing the development of HIVE requires
an understanding of how, where, and when the virus
accesses the brain and whether a latent viral reservoir
exists within the CNS, sequestered from systemic im-
mune surveillance. If such a reservoir is present, current
therapeutics may be unable to eliminate an established
CNS reservoir, allowing later reactivation. Key research
priorities for HIV-1 eradication include identifying ana-
tomical and cellular reservoirs, to allow the develop-
ment of targeted strategies that eliminate virus from
these sites.10
PCR studies have confirmed low levels of HIV-1 DNA in
homogenized brain samples of some presymptomatic
subjects without evidence of productive HIV infection.11
Figure 1. Representative photomicrographs of immunohistochemically stained sections of the white matter from the occipital region of the cerebral cortex. A–C:
HIV-negative, subject code no. 310. D–F: HIV-positive presymptomatic, code no. 240. G–I: HIV-positive presymptomatic, code no. 245. J–L: HIV-positive
encephalitic, code no. 138. A, D, G, and J: GFAP immunoreaction, showing baseline astrocyte numbers in controls and increased astrocyte reactivity in both
HIV-positive presymptomatic and HIV-positive encephalitic cases. B, E, H, and K: CD68 immunoreaction, showing baseline microglia in controls with a minor
increase in macrophage/microglial reactivity in HIV-positive presymptomatic cases, and prominent reactivity in HIV-positive encephalitic cases. C, F, I, and L: In
situ proximity ligation assay for detection of individual p24 protein, showing no evidence of p24 protein (C, F, and I) or showing p24 positivity (L), indicating
productive infection with HIV protein (arrows). Hematoxylin counterstain. Scale bars  40 m.
1626 Thompson et al
AJP October 2011, Vol. 179, No. 4
Nonetheless, there is still no conclusive evidence as to
which brain cells are harboring virus before the onset of
HIVE.12 Our ability to detect HIV-1 DNA from specific
brain cell types in a cohort of individuals who died from
HIV-unrelated causes during presymptomatic infection
presented a unique opportunity to identify cellular viral
reservoirs of the brain. Our detection of HIV-1 gag DNA in
long-lived brain cells without evidence of productive in-
Figure 2. Analysis of HIV-1 gag DNA isolated from laser microdissected brain cell populations; astrocytes, perivascular macrophages (PVM), and parenchymal
microglia (PM) from HIV-presymptomatic (PS) and HIV-encephalitic (HIVE) cases. A: Representative images of HIV-1 gag DNA PCR resulting in three rounds of
PCR products (286, 205, and 119 bp). HIV-1 gag DNA was not consistently detected in PCR amplification from samples in which there were low levels of virus.
Cell populations were therefore collected in duplicate (two collections of astrocytes per case), and the triple-nested PCR was performed on each cell population
at least 10 times, to increase the frequency of detection. Not every PCR amplification from DNA of cell populations is illustrated (results of PCR amplifications of
HIV-1 gag DNA from all cell populations are given in Table 1 and sequencing results are shown here in panel B). Lane A, negative PCR control (water as DNA
template) carried through three rounds of PCR. Lane B, code no. 281 (PS), PVM. Lane C, code no. 305 (PS), PVM. Lane D, code no. 281, astrocytes. Lane E, code
no. 305, astrocytes. Lane F, code no. 75 (HIVE), astrocytes. Lane G, code no. 75, PVM. Lane H, code no. 138 (HIVE), astrocytes. Lane I, code no. 138, PVM. Lane
J, code no. 75, PM. Lane K, code no. 138, PM. Lane L, code no. 281, PM. Lane M, code no. 305, PM. Lane N, Lymph node of HIV-positive patient, positive PCR
control (overamplification results in PCR product not running through the gel). B: Association between CD4 T-cell count and the frequency with which HIV-1 DNA
was detected by triple-nested PCR in perivascular macrophages (PVM, expressed as a percentage) in the occipital cortex for each of the seven HIV-positive
individuals. C: Amino acid sequence alignment of HIV-1 gag DNA from PCR products of laser microdissected brain cell populations. Sequences are aligned and
numbered according to the HIV-1 gag consensus sequence. ast, astrocyte; mac, perivascular macrophages; mic, parenchymal microglia.
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fection suggests that brain cell reservoirs of latent virus
exist before HIVE onset. By the time of HIVE, both
perivascular macrophages and parenchymal microglia
demonstrate productive HIV-1 infection in the brain, but
astrocytes, which have been shown to contribute to neu-
ropathogenesis, are not productively infected.3,13,14
Parenchymal microglia are a stable, long-lived CNS
cell population that form a dense network throughout the
brain. Their anatomical location and morphology is dis-
tinct from that of perivascular macrophages. Latently in-
fected parenchymal microglia in presymptomatic HIV-1
infection may well represent a constant CNS viral reser-
voir. Circulating blood monocytes traffic into the perivas-
cular space to become tissue perivascular macrophages
and are constantly turned over via the systemic circula-
tion.15–18 We previously examined brain cell-specific in-
fection at multiple time points from acute to terminal in-
fection in simian immunodeficiency virus (SIV) infected
macaques. The study demonstrated that infected macro-
phages act as the Trojan horse within the brain perivas-
cular space, with an initial increase in latent infection of
perivascular macrophages and subsequent productive
infection of perivascular macrophages and brain paren-
chymal cells concurrent with increasing plasma viral load
and decreasing peripheral blood CD4 count.5 In our
present study, we have similarly demonstrated increas-
ing immunosuppression correlating with increasing latent
HIV-1 infection of circulating perivascular macrophages
before the onset of HIVE. Both studies suggest that
perivascular macrophages may be pivotal in advancing
HIV-1 brain infection at times of increasing immunosup-
pression and that maintaining CD4 cell levels may be
crucial for controlling a critical entry point of HIV-1 from
the systemic circulation into the brain. It is yet to be
determined whether the onset of HIVE is due to reactiva-
tion of the microglial reservoir, influx of systemic HIV via
infected macrophages, or both.
Our studies show microglial and astrocytic reactivity in
the absence of HIV-1 p24 protein in brain tissue from
presymptomatic individuals and that CD4 lymphocytic
infiltration of the brain was negligible.2 Given latent virus
detected within brain cells before HIVE, this low-level
activation of microglia and astrocytes may indicate a
response to trafficking of HIV-1 into the brain and/or a
change in the replication state of the latent infection.
CNS infiltration of activated monocytes/macrophages
and microglial activation have been widely reported to be
essential in the development of HIV-associated neurolog-
ical disorders.12,19–22 A recent study showed that risk of
HIV-associated neurological disorders is associated with
nadir CD4 count.23 Preventing CD4 decline by earlier
initiation of combination antiretroviral therapy may reduce
entry of HIV-1 infected perivascular macrophages from
the systemic circulation into the brain and so reduce the
likelihood of HIV-associated neurological disorders.
In conclusion, we provide evidence that brain cell res-
ervoirs of latent HIV-1 exist before the onset of patholog-
ical HIVE and suggest that perivascular macrophages
may be pivotal to brain disease progression at times of
increasing immunosuppression. Therapies to prevent
CNS HIV disease progression may thus need to target
perivascular macrophages, before immunosuppression.
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